![](/img/cover-not-exists.png)
PCN92 INOTUZUMAB OZOGAMICIN VERSUS STANDARD CHEMOTHERAPY FOR RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A COST-UTILITY ANALYSIS FROM THE PERSPECTIVE OF NATIONAL HEALTH INSURANCE ADMINISTRATION IN TAIWAN
Lee, T.Y., Chen, T.Y., Li, S.S., Lo, Y.W., Wen, Y.C., Ou, H.T.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.216
Date:
May, 2019
File:
PDF, 381 KB
english, 2019